Abstract:The coronavirus family has many pathogens that cause severe human diseases, including SARS, MERS and COVID-19.Starting from the SARS outbreak in 2003, our group has been dedicated to understanding coronavirus Replication-Transcription Complexes (RTCs).During the early part of the COVID-19 outbreak, we rapidly initiated a structural study of SARS-CoV-2 RTCs, aiming to dissect the key mechanisms for SARS-CoV-2 in human cells and provide structural information to discover potent antivirals.With great efforts from our laboratory and outside collaborations, we successfully determined the structure of the central RTC (C-RTC) composed by nsp12 (RNAdependent RNA polymerase, RdRp) with cofactors nsp7 and nsp8 1 , providing the first picture to visualize this key antiviral target.We also elucidated the mechanism of C-RTC catalysis and how remdesivir (RDV) inhibits the synthesis of RNA.This was achieved by determining the structure of C-RTC in complex with the template-product duplex RNA and the active form of RDV 2 .Subsequently, we presented the structure of the elongation RTC (E-RTC), showing how nsp13 (helicase) unwinds the highly-ordered structure in genome to yield the functional template for RNA synthesis in C-RTC 3 .After that, we discovered a key intermediate state of RTC leading towards mRNA capping [Cap(-1)'-RTC], demonstrating the nsp12 NiRAN is indeed the key enzyme to catalyze the second capping action and how it presents nsp9 as an "adaptor" for the further recruitment of capping enzymes into RTC 4 .In a following study, we assembled Cap(0)-RTC by Cap(-1)'-RTC and nsp10/nsp14, showing how the co-transcriptional capping and an in trans backtracking mechanism for proofreading concert in one RTC 5 .In our most recent work, we discovered a previously unknown protein modification -RNAylation on nsp9, and demonstrated nsp12 NiRAN utilizes the RNAylated nsp9 and GTP as substrates to synthesize the GpppA cap core, reasoning a novel RNA capping pathway 6 .We also showed that the nucleotide analogue inhibitors (NAIs) can be linked to nsp9 by NiRAN and thus block the occurrence of RNAylation and GpppA formation, furthering the understanding of the mechanism of action of NAIs.An 'induce-and-lock' mechanism is proposed to design new inhibitors against SARS-CoV-2 RNA capping.These works not only provides a basis to understand SARS-CoV-2 proliferates in the host cells through a structural biology lens, but also sheds new light for antiviral development against rapidly emerging SARS-CoV-2 variants.1

Trapping non-cognate nucleotide upon initial binding for replication fidelity control in SARS-CoV-2 RNA dependent RNA polymerase

Allosteric Activation of SARS-CoV-2 RNA-Dependent RNA Polymerase by Remdesivir Triphosphate and Other Phosphorylated Nucleotides

Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase

Development of a Simple in Vitro Assay to Identify and Evaluate Nucleotide Analogs Against SARS-CoV-2 RNA-Dependent RNA Polymerase

Protein-protein interaction of RdRp with its co-factor NSP8 and NSP7 to decipher the interface hotspot residues for drug targeting: A comparison between SARS-CoV-2 and SARS-CoV

Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay

Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid

Binding Mechanism of the Active Form of Molnupiravir to RdRp of SARS-CoV-2 and Designing Potential Analogues: Insights from Molecular Dynamics Simulations

Viral RNA Replication Suppression of SARS-CoV-2: Atomistic Insights into Inhibition Mechanisms of RdRp Machinery by ddhCTP

Nucleotide Analogues Bearing a C2′ or C3′-Stereogenic All-Carbon Quaternary Center as SARS-CoV-2 RdRp Inhibitors

A 'deep dive' into the SARS-Cov-2 polymerase assembly: identifying novel allosteric sites and analyzing the hydrogen bond networks and correlated dynamics

Point mutations at specific sites of the nsp12-nsp8 interface dramatically affect the RNA polymerization activity of SARS-CoV-2

Mechanism and spectrum of inhibition of a 4’-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses

NMPylation and de-NMPylation of SARS-CoV-2 nsp9 by the NiRAN domain

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective

Chain Termination Effects of Chemically Modified Nucleoside Analogs on SARS-CoV-2 RNA Polymerase

Mechanistic insights into the activity of SARS-CoV-2 RNA polymerase inhibitors using single-molecule FRET

Alternative substrate kinetics of SARS-CoV-2 Nsp15 endonuclease reveals a specificity landscape dominated by RNA structure

Nucleotide analogues as inhibitors of SARS-CoV Polymerase

2′- and 3′-Ribose Modifications of Nucleotide Analogues Establish the Structural Basis to Inhibit the Viral Replication of SARS-CoV-2

A Story of SARS-CoV-2 RNA Capping